News Headlines

  1. ZipBio And MeiraGTx Enter Into Exclusive License Agreement To Advance First-In-Class AAV Gene Therapy For Geographic Atrophy 2/3/2026

    ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company.

  2. Cellares To Expand Automated Manufacturing To Gene-Edited Stem Cell Therapies 2/3/2026

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and release testing for gene-edited hematopoietic stem cell (HSC) therapies, expanding the application of Cellares’ automation platforms beyond T cell therapies into a new cell modality.

  3. CEPI And Samsung Biologics Collaborate To Strengthen Outbreak-Ready Vaccine Production And Global Access 2/3/2026

    The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats.

  4. SK bioscience In-Licenses RSV Preventive mAb Candidate From Gates Medical Research Institute 2/3/2026

    SK bioscience will advance a novel respiratory syncytial virus (RSV) monoclonal antibody for global health under license from the Gates Medical Research Institute (Gates MRI).

  5. WuXi Biologics And Vertex Sign License And Research Service Agreement For T-Cell Engager 2/2/2026

    WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.

  6. Lupin And TB Alliance Join Forces To Advance Telacebec For The Treatment Of Tuberculosis And Other Mycobacterial Diseases 2/2/2026

    Global pharma major Lupin Limited (Lupin) today announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer.

  7. Alvotech Enters Supply And Commercialization Agreements For Canada And Australia & New Zealand Covering Multiple Biosimilar Candidates 2/2/2026

    Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

  8. Teva Canada Announces Strategic Partnership With Novartis Canada To Relaunch Mayzent® For Multiple Sclerosis Patients In Canada 2/2/2026

    Teva Canada Limited (Teva Canada) is announcing a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. (Novartis Canada) for Mayzent® (siponimod), an innovative oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease.

  9. Recordati Announces Strategic Collaboration With Moderna To Develop And Commercialize Worldwide mRNA 3927 For The Treatment Of Propionic Acidemia 1/29/2026

    Recordati today announced that it has entered into a collaboration and license agreement with Moderna to develop and commercialize worldwide mRNA-3927, an investigational product for the treatment of propionic acidemia (PA).

  10. Pharmaceutical Service Provider Vetter Pharma To Build New Manufacturing Site In Germany 1/29/2026

    Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.